Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the ...

Merck is growing pharma sales and expanding margins, led by strong KEYTRUDA performance and cost discipline. Read more about ...

Merck & Co – known as MSD outside of the US and Canada – and Cyprumed have entered into a partnership aimed at developing ...

Merck signs deal with Austria's Cyprumed to develop oral peptide therapies, potentially paying up to $493 million for access ...

Merck & Co. has entered a competitive race for a new type of heart drug ... president of Merck Research Laboratories, in a statement. The frontrunners in the chase, among them Novartis and ...

Merck Life Science South Africa, a leading science and technology company, is excited to announce its participation as a bronze sponsor at Analytica Lab Africa 2025. This major trade fair for ...

The trial compared the new subcutaneous pembrolizumab ... global clinical development at Merck Research Laboratories, also highlighted the innovative approach of the subcutaneous pembrolizumab ...

Large drugmakers including Merck and Eli Lilly have turned to Chinese biotechs for deals that give them access to new drugs for a ... rights to China-based United Laboratories International's ...

Merck released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA is reviewing the application for approval. The data sho ...

Merck Research Laboratories. "These results led to the ZENITH study being the first PAH clinical trial stopped early due to overwhelming efficacy, representing an important milestone in clinical ...

Li, president, Merck Research Laboratories. “HRS-5346 ... of generic drugs this year that has made the issue of securing new candidates all the more pressing. However, President Trump’s ...